Data released to investors last month showed company struggling to figure out dosage for young age group.
Pfizer’s experimental mRNA jab caused one in five children aged 2–5 enrolled in clinical trials to develop severe fevers, data from the company’s own trial shows
Reporting on his Substack “Unreported Truths,” researcher Alex Berenson highlighted the alarming data released by the company itself to investors last month shows Pfizer is struggling to figure out dosages for the young age group.
“Fevers in kids 2-5 who received 10 micrograms of mRNA were both more common and more severe than those in other children tested with the vaccine, the company found,” Berenson reported, adding the adverse event occurred regardless of first, or second dose tests.
The data appears in slide #23 of a slideshow presentation prepared for analysts and investors on December 17, and shows the 2 to 5 age range was more highly affected than any other group.
While the fevers were observed in the higher dosage, a 10-microgram dose has still been approved by the FDA and CDC for children aged 5 to 12.
The 5-year-old age overlap should also be problematic for trial researchers, Berenson writes:
“The vaccine dosing is not adjusted by weight. All five-year-olds receive the full 10-microgram dose, even if they are no bigger than a typical three or four-year-old.”
Additionally, “Pfizer has not published any safety or efficacy data for its vaccine in children under 5 in a peer-reviewed journal,” reports the former New York Times journalist.
In their update, Pfizer said it would amend the study to evaluate a 3-microgram dose for children aged 6-months to 5-years-old.
Pfizer’s press release also admitted the company’s going on to test a third jab of the 3-microgram dose in children aged 2-5 after failing non-inferiority trials, further illustrating dosing challenges.
“Pfizer has not published any safety or efficacy data for its vaccine in children under 5 in a peer-reviewed journal,” Berenson notes, which means parents unfortunately have to trust data from the very company producing the vaccine.